Stoke Therapeutics
IPO News: Filed S-1: Stoke Therapeutics Files $86.3mm IPO
Stoke Therapeutics

Stoke Therapeutics

NASDAQ:  STOK

Size:  $86.3mm

Bookrunners:  JPM | COWEN | CS

Major Holders:  Apple Tree Partners | RTW Investments | Seth Harrison (Director)

Description:  Stoke Therapeutics is a pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. They are developing novel antisense oligonucleotide, or ASO, medicines that target ribonucleic acid, or RNA, and modulate precursor-messenger RNA, or pre-mRNA, splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels.

Note:  Emerging Growth Company

Reference Link:  S-1